How many pills of enzalutamide/enzalutamide should be taken a day?

Enzalutamide/Enzalutamide is used in certain circumstances to treat prostate cancer in adults. Enzalutamide is currently available in oral capsules and oral tablets. The dosage and usage of enzalutamide may vary based on individual circumstances, based on the guidance of the clinician. Before using the medication, patients should consult a doctor or health care provider to ensure correct dosage and usage advice.

The U.S. Food and Drug Administration (FDA) approved enzalutamide for the treatment of adults with prostate cancer whose cancer has responded to treatments that lower testosterone levels and has spread to other parts of the body (metastatic prostate cancer) or has not spread but is at high risk of spreading and the cancer is resistant to treatments that lower testosterone levels.

Enzalutamide belongs to a class of drugs called androgen receptor blockers. It is recommended to take 160mg once a day with food or on an empty stomach until the disease progresses or the side effects of the drug become unbearable. Swallow the tablet whole; do not chew, dissolve or open the capsule, and do not cut, crush or chew the tablet. If the patient purchases enzalutamide in the specification of 40mg*112 capsules/box, he/she needs to take 4 enzalutamide capsules; however, if the patient needs to adjust the dosage of the drug due to adverse reactions after taking drug treatment, the number of capsules taken may be adjusted at this time.

In addition, prostate cancer patients receiving enzalutamide should also receive concomitant gonadotropin-releasing hormone (GnRH) analog therapy or undergo bilateral orchiectomy. For patients receiving enzalutamide, with or without GnRH analogues, treatment may be suspended if PSA becomes undetectable (<0.2ng/mL) after 36 weeks of treatment. Treatment is restarted when the PSA rises to ≥2.0ng/mL in patients who have previously undergone radical prostatectomy or when the PSA rises to ≥5.0ng/mL in patients who have received primary radiotherapy.